➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Express Scripts
Baxter
Boehringer Ingelheim
Moodys

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,562,861


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,562,861 protect, and when does it expire?

Patent 6,562,861 protects RAPIVAB and is included in one NDA.

This patent has twenty-eight patent family members in twenty-two countries.

Summary for Patent: 6,562,861
Title: Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
Abstract:##STR1## Compounds I-III wherein U is CH, O, or S; Z is mono- or di-substituted carbon; R is (CH2)nCO2H, (CH2)nSO3H, (CH2)nPO3H2, (CH2)nNO2, CH(SCH3)3, esters; R1 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl; RR1 is O; n is 0-4; R2, R3 is H, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkyl; R4 is (CH2)nOH, (CH2)nNH2, substituted alkyl were prepd. as neuraminidase inhibitors. Thus, (1R,3R,4R,1'S)-(-)-(1'-acetylamino-2 '-ethyl)butyl-4-(aminoimino)methylaminocyclopentan-1-carboxylic acid was prepd. and tested in vitro as neuraminidase inhibitor (IC50<1.mu.M).
Inventor(s): Babu; Yarlagadda S. (Birmingham, AL), Chand; Pooran (Birmingham, AL), Montgomery; John A. (Birmingham, AL)
Assignee: BioCryst Pharmaceuticals, Inc. (Birmingham, AL)
Application Number:09/555,131
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 6,562,861

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Biocryst RAPIVAB peramivir SOLUTION;INTRAVENOUS 206426-001 Dec 19, 2014 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,562,861

PCT Information
PCT FiledDecember 17, 1998PCT Application Number:PCT/US98/26871
PCT Publication Date:July 08, 1999PCT Publication Number: WO99/33781

International Family Members for US Patent 6,562,861

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 016162 ⤷  Free Forever Trial
Austria 425955 ⤷  Free Forever Trial
Australia 2200199 ⤷  Free Forever Trial
Brazil 9813480 ⤷  Free Forever Trial
Canada 2315262 ⤷  Free Forever Trial
China 1282316 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Harvard Business School
Dow
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.